In July 19, 2017, Ministry of Human Resources and Social Security issued Notice on Bringing 36 Kinds of Drugs into Type II Category of Drug list of National Basic Medical insurance, Industrial Injury Insurance and Maternity Insurance, Shenyi capsule of Yatai Group, as the first batch of national health insurance negotiation varieties, was successfully listed into contents of national health insurance drugs 2017, which achieves the wish of listing Shenyi capsule for 17 years, shows milestone-significance for Shenyi capsule, greatly improves influence of the product brand, opens a new chapter for realization of a large variety of tumor cultivation objectives, creates conditions for internationalization registration of Shenyi capsule in the United States, Singapore, Malaysia and other countries, is conducive to promoting the internationalization of Shenyi capsule and benefits more cancer patients.
At present, Yatai Pharmaceutical Co., Ltd. has two national Category I traditional Chinese medicine monomer drug, i.e. Shenyi capsule and forsythin capsule. Forsythin project was approved by CFDA at the end of 2016 and entered phase I / III of clinical study. Shenyi capsule that is the first class of targeted Chinese medicine of Category I monomer antineoplastic blood vessel researched and developed by China after artemisinin won second price of national technological invention in 2013. It is recommended by multiple clinical guidelines as cured drug of cancers such as lung cancer, liver cancer, breast cancer, gastric cancer, colorectal cancer, thyroid cancer, esophageal cancer, etc., and repeatedly selected as a drug for science and technology research projects of “10th Five-Year Plan, 11th Five-Year Plan, 12th Five-Year Plan”. Shenyi capsule, as a large verity of cancer, makes a great profit contribution to the enterprise. In 2016, sales income of Shenyi capsule was RMB275 million.
With newly listing of Shenyi capsule in national health insurance drug list 2017, it will greatly improve the brand influence and expand the market share, horizontally drive expanded development and market coverage of 20 new health insurance provinces and cities in area of “Beijing, Shanghai and Guangdong”, and vertically drive deep development of original 11 health insurance provinces and cities. It is expected that double growth of sales revenue will be realized in future 3-5 years. At the same time, Yatai Group will continue to plan and invest in scientific research cooperation, evidence-based medicine research, and strive to push Shenyi capsule to a higher field.
